<DOC>
	<DOCNO>NCT01808885</DOCNO>
	<brief_summary>This 24-week phase 1b , randomize , double-blind , placebo-controlled , parallel-group , multicenter safety study compare tolerance profile olesoxime ( 495 mg , od ) administer top Interferon beta patient stable Relapsing Remitting Multiple Sclerosis . Patients randomly allocate olesoxime ( 495 mg , od ) placebo 1:1 ratio .</brief_summary>
	<brief_title>Safety Study Olesoxime Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta .</brief_title>
	<detailed_description>The primary objective study characterize general safety tolerability olesoxime ( 495 mg , od ) , compare placebo administer combination Interferon beta 24-week treatment period patient stable Relapsing Remitting Multiple Sclerosis . The secondary objective study evaluate feasibility multicenter protocol measurement neurodegeneration remyelination MRI well plasma exposure olesoxime ( 495 mg , od ) . MRI perform patient assess effect olesoxime brain inflammation well assess measure brain atrophy , neuronal damage myelination status Baseline , 12 week 24 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Men woman ≥ 18 year old Diagnosed Relapsing Remitting Multiple Sclerosis . Patients must stable defined free relapse episode least 6 month prior Baseline Patients must treat Interferon beta least one year Patients must Expanded Disability Status Scale ( EDSS ) score ≤ 5 Female patient must postmenopausal ( define least 12 month post cessation menses ) , surgically sterile , childbearing potential , use reliable method contraception least 3 month prior Baseline study . In addition , female patient must lactate Patients must able understand comply study requirement Patients must provide write , date sign informed consent prior study procedure Any relapse multiple sclerosis within past 6 month prior Screening Visit/Visit 1 Any change Interferon treatment within past year prior Screening Visit ( Visit 1 ) Expected use another disease modify therapy Screening Visit/Visit 1 Visit 3/Final Visit Patients unable undergo MRI scan Current expect use medication could interfere olesoxime pharmacology ( e.g . tamoxifen ) Current expect use lipid lower agent ( ezetimibe , bile salt chelators , fibrates , phytosterols ) statins Known hypersensitivity olesoxime component History alcohol drug abuse within last 6 month , addiction within last 2 year prior Baseline Visit Positive urinary pregnancy test Baseline Visit History hepatitis B/C HIV positive serology Hepatic impairment ( aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 × ULN ) Baseline Visit History renal impairment define serum creatinine value &gt; 176 μmol/L ( 2.0 mg/dL ) Baseline Visit Abnormal clinically significant ECG Screening Visit/Visit 1 assess cardiologist Current expect use oral intramuscular corticosteroid within 3 month prior Screening Visit . Only stable dose regimen inhale topical corticosteroid allow study History clinically relevant gastrointestinal ( GI ) , respiratory , psychiatric , neurological , kidney , liver , cardiac disease , bleed disorder , disease/condition abnormal physical finding may interfere study objective put patient 's safety risk , judge Investigator Patients active chronic disease ( stable treat immune therapy ) immune system Multiple Sclerosis ( MS ) History malignancy organ , treat nontreated within past 5 year Current participation participation within 30 day prior study entry , another investigational drug device study , previous enrolment present study Any direct involvement study conduct site family link study site staff Pregnant , parturient lactate woman , per Public Health Code ( CSP ) ( Article L11215 ) Persons deprive liberty judicial administrative decision , admit health social facility , per CSP ( Article L11216 ) Persons cover measure legal protection unable provide write , date sign informed consent , per CSP ( Article L11218 ) Patient without Social Security Insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>olesoxime</keyword>
	<keyword>double-blind</keyword>
	<keyword>randomize</keyword>
</DOC>